Femasys INC

Femasys Inc. announced the closing of a $30 million private placement of common stock and warrants, strengthening its financial position and providing capital for future operations.

Femasys Inc. shareholders elected two Class II directors and ratified the appointment of KPMG LLP as the independent auditor at the 2026 Annual Meeting.

Femasys Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split.

Femasys Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective June 5, 2026.

Femasys Inc. will implement a 1-for-20 reverse stock split, effective June 5, 2026, with trading on a split-adjusted basis commencing June 8, 2026.

Femasys Inc. details its multi-asset portfolio and commercialization strategy targeting large, underserved markets in fertility and permanent birth control.

Femasys reports Q1 2026 net income of $0.85 million, driven by non-cash gains, while maintaining a going concern warning due to liquidity constraints.

Femasys Inc. reported a 31.4% increase in Q3 2025 sales, driven by FemBloc, but saw net losses widen for the nine-month period and faces ongoing liquidity and Nasdaq compliance challenges.

Femasys Inc. reports increased sales and product approvals but warns of substantial doubt about its ability to continue as a going concern, facing Nasdaq delisting and urgent capital needs.

Femasys Inc. announces its financial results for the first quarter of 2025, highlighting increased sales and ongoing development of its FemBloc permanent birth control system.

Femasys Inc. saw a significant increase in sales and continued progress in the commercialization of its products during the third quarter of 2024, while also advancing its clinical programs.

Femasys Inc. reported a net loss of $4.68 million for the second quarter of 2024, while progressing with the commercial launch of FemaSeed and the clinical trial for FemBloc.

Femasys Inc. reported continued operating losses and substantial doubt about its ability to continue as a going concern, alongside Nasdaq delisting notices, despite increased sales and product development progress.

Femasys Inc. highlights advancements in its women's health portfolio, including regulatory approvals and strategic partnerships, in its annual 10-K filing.

Femasys Inc. has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and updated certifications.

Femasys Inc.'s 10-K filing details the company's financial status, product development, and strategic initiatives in women's health, including FemaSeed and FemBloc.

Kenneth D. Eichenbaum, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Edward R Uzialko, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Alistair Milnes, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Charles Larsen, a Director of Femasys Inc, received 880 shares of common stock on June 24, 2026.

Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs of Femasys Inc, purchased 3,125 shares of common stock on August 7, 2026 for $3.20 per share.

Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs of Femasys Inc, received 6,250 shares of common stock on July 6, 2026.

Femasys Inc. has scheduled its 2026 Annual Meeting for June 24 to elect directors, ratify its independent auditor, and provide updates on executive compensation and corporate governance.

Femasys Inc. has called a special meeting for April 29, 2026, to seek shareholder approval for a reverse stock split and the issuance of shares related to convertible notes and warrants.

Femasys Inc. is holding its annual meeting on June 25, 2025, where stockholders will vote on the election of directors, an amendment to the equity incentive plan, and the ratification of the independent accounting firm.

Femasys Inc. is holding its 2025 Annual Meeting of Stockholders on June 25, 2025, to elect directors, approve an amendment to the equity incentive plan, and ratify the appointment of its independent accounting firm.

Femasys Inc. will hold its 2024 Annual Meeting of Stockholders on July 12, 2024, to elect a director and ratify the appointment of its independent accounting firm.

Femasys Inc. is offering up to 11.4 million shares and warrants to raise capital, while simultaneously addressing Nasdaq delisting notices and a 'going concern' warning.

Femasys Inc. files S-1 for a public offering of 11.4 million shares to raise capital, while facing imminent delisting from Nasdaq due to low market value and bid price.

Nantahala Capital Partners Limited Partnership and affiliated entities have acquired a significant stake in Femasys Inc., securing board representation and certain governance rights.

Rosalind Advisors Inc. and related entities have disclosed a beneficial ownership of 9.9% in Femasys Inc., primarily through warrants.

Dauntless Investment Group, LLC has reported a 9.99% beneficial ownership stake in Femasys Inc., primarily for passive investment purposes.

Alumni Capital LP, along with its general partner and controlling person, has disclosed a 9.99% beneficial ownership stake in Femasys, Inc. through a combination of a purchase agreement and warrants.

Jorey Chernett has disclosed a passive beneficial ownership of 9.33% of Femasys Inc.'s common stock as of June 30, 2025.

Individual investor Jorey Chernett has disclosed a passive beneficial ownership of 6.17% of FEMASYS INC's common stock, totaling 1,624,313 shares.

Dauntless Investment Group, LLC has filed a Schedule 13G, reporting a passive beneficial ownership of 5.43% in FEMASYS INC's common stock, totaling 1,429,845 shares.